The past year saw a pivotal shift in genomic medicine, during which momentum gained in expanding adoption of genetic testing beyond specialty clinics and into broader clinical practice as a foundational part of preventive health and diagnosis.
Below are three trends in precision genomics that defined 2025—and how MyOme is helping accelerate progress toward accessible personalized medicine.
In 2025, whole-genome sequencing (WGS) became increasingly accessible - driven not only by lower sequencing costs but also by growing support in clinical guidelines.1 For example, the American Academy of Pediatrics (AAP) now recommends broader use of WGS and WES in pediatric patients with neurodevelopmental disorders and other complex medical needs, such as global developmental delay and intellectual disabilities.2 This new guidance is further accelerating adoption of genomic testing beyond specialized genetics clinics for front-line rare disease diagnostics. As WGS becomes more affordable and clinically endorsed, more providers and health systems are integrating testing earlier in their diagnostic pathways and understanding the power of a genome-first approach to medicine across both rare disease and proactive health.
Moreover, recent advances in long-read sequencing that have simplified methodology and improved complex variant detection have led to widespread adoption.3 With LRS, clinicians gain clearer insight into hard-to-detect variants, like structural variants, tandem repeat expansions, and methylation signatures, which are often missed by short-read technologies.4
MyOme’s 2025 product roadmap reflected this momentum. MyOme launched their diagnostic Rare Disease tests, which quickly expanded to include LRS-powered confirmation of complex tandem repeat expansions. MyOme further leveraged the power of their genome-first approach with expansions of their WGS-powered Proactive Health polygenic risk score (PRS) portfolio to include precision risk prediction for prostate cancer and type 2 diabetes.
Looking ahead to 2026:
WGS and LRS are expected to become even more accessible and popular. MyOme will continue expanding its WGS-based Proactive Health portfolio to offer more holistic risk prediction and deepen integration of LRS into their Rare Disease portfolio to improve detection of complex variants—further strengthening diagnostic sensitivity and accuracy.
2025 marked a year where preventive genomics transitioned from a niche specialty tool to a routine component of modern care. With increasing affordability and evidence supporting genomics-informed preventative care, more health systems and primary care physicians are adopting precision genomics into everyday practice.5
The clinical value is clear: earlier identification of at-risk individuals, more personalized care plans, and more efficient allocation of preventive resources.
MyOme advanced this shift in 2025 through several key partnerships, namely, the launching of the Proactive Health Network, a consortium of concierge, executive health, and longevity practices integrating MyOme genomic tests into routine preventative care. Beyond clinical uptake, MyOme also advanced genomic testing as a routine employee benefit through partnerships with Collective Health, Novi Health and Thatch Marketplace.
Looking ahead to 2026:
Precision genomics is expected to become a standard preventive option across more provider groups, health systems, and employers. MyOme will continue scaling its clinical footprint by initiating partnerships, launching new genomic tests, and validating their existing portfolio—including the ongoing evaluation of the MyOme iPRS CAD test through the COMPASS-CAD trial and the launch of the MyOme Proactive Health (MPH) trial, a large-scale, collaborative trial with Illumina that aims to prove enhanced patient outcomes and substantial cost savings from use of WGS and AI-integrated risk models.
Across healthcare, AI is unlocking new capabilities in prediction, interpretation, and clinical decision support. In 2025, AI tools revolutionized precision genomics by offering advanced genetic variant detection, improved risk modeling, and reduced diagnostic uncertainty through analysis of large genomic and clinical datasets.
This year, MyOme was selected for the Mayo Clinic Platform_Accelerate program, which will support the validation of an AI-based solution that integrates WGS, PRS, and clinical data to identify elevated risk before symptoms emerge and streamline genomic interpretation for clinicians.
Looking ahead to 2026:
AI will continue reshaping healthcare through more adaptive, real-time clinical intelligence. Through Platform_Accelerate and independent development, MyOme is building AI-driven tools that analyze EHR data and trigger dynamic reanalysis of whole-genome results as clinical information evolves—keeping risk assessments current and enabling truly continuous, personalized care.
From the rising popularity and adoption of WGS and LRS to the boom of AI-enabled clinical insights, 2025 marked substantial progress in precision genomics. MyOme helped drive this shift through new product launches, strategic partnerships, and research initiatives. With 2026 poised for deeper integration of LRS, broader real-world genomic adoption, and more adaptive AI models, the next era of precision medicine is taking shape—built on genomic insights that are accessible, actionable, and continuously evolving.
References